Evelo Biosciences Inc
OTC:EVLO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Evelo Biosciences Inc
OTC:EVLO
|
US |
|
Deutsche Cannabis AG
F:HEMP
|
DE |
|
A
|
Aju IB Investment Co Ltd
KOSDAQ:027360
|
KR |
|
C
|
China Industrial Group Inc
OTC:CIND
|
US |
|
X
|
Xiamen Changelight Co Ltd
SZSE:300102
|
CN |
|
CoStar Group Inc
NASDAQ:CSGP
|
US |
|
J
|
JATT Acquisition Corp
F:1GU
|
KY |
|
L
|
LGB Forge Ltd
NSE:LGBFORGE
|
IN |
|
P
|
Plum Acquisition Corp. IV
NASDAQ:PLMK
|
US |
|
Oppenheimer Holdings Inc
NYSE:OPY
|
US |
|
S
|
Suzhou YourBest New-type Materials Co Ltd
SZSE:301266
|
CN |
Evelo Biosciences Inc
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-05-09. The firm is focused on discovering and developing an orally delivered investigational medicines that acts on cells in the small intestine to produce therapeutic effects throughout the body. The company has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are orally delivered pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles. Its product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Its other product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease. The company has developed an integrated platform namely, SINTAX Medicine Platform, which is designed to identify individual strains of microbes capable of modulating the immune system by acting on SINTAX when administered at pharmacologically active doses and appropriately formulated.
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-05-09. The firm is focused on discovering and developing an orally delivered investigational medicines that acts on cells in the small intestine to produce therapeutic effects throughout the body. The company has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are orally delivered pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles. Its product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Its other product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease. The company has developed an integrated platform namely, SINTAX Medicine Platform, which is designed to identify individual strains of microbes capable of modulating the immune system by acting on SINTAX when administered at pharmacologically active doses and appropriately formulated.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
